Search

Pliant Therapeutics Inc

Fechado

1.15 0.88

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.1400000000000001

Máximo

1.17

Indicadores-chave

By Trading Economics

Rendimento

-2.3M

-22M

EPS

-0.36

Funcionários

49

EBITDA

-2.4M

-22M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+115.52% upside

Dividendos

By Acuity

Próximos Ganhos

4 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.7M

68M

Abertura anterior

0.27

Fecho anterior

1.15

Pliant Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de set. de 2026, 23:51 UTC

ECB President Lagarde's Upcoming Speech on September 9, 2026, Expected to Address Interest Rates and Inflation Amidst Euro Area Economic Uncertainties.

6 de set. de 2026, 23:51 UTC

Correlated Moves

Avalanche is trading higher, boosted by strong performance in correlated assets like Ethereum. It is currently 8.96% above its 20-day moving average.

6 de set. de 2026, 23:41 UTC

Investors Brace for September 11 CPI Release Amid Rising Inflation Concerns and Economic Uncertainties

6 de set. de 2026, 23:41 UTC

Investors Brace for Key CPI Release on September 11, Anticipating Impact on Inflation Trends and Market Dynamics.

6 de set. de 2026, 23:41 UTC

U.S. Inflation Rate Expected to Stabilize at 3.4% Amid Market Caution and Potential Fed Interest Rate Hikes

6 de set. de 2026, 23:41 UTC

U.S. Core Inflation Rate Expected at 2.4% Amid Rising Market Volatility and Anticipated Fed Rate Hike Discussions

6 de set. de 2026, 23:41 UTC

Core Inflation Rate Expected to Rise 0.2% in August, Sparking Optimism Among Traders Ahead of September Release

6 de set. de 2026, 23:41 UTC

U.S. Inflation Rate Expected to Rise by 0.4% in August, Heightening Concerns Over Interest Rate Hikes Amid Strong Job Growth

6 de set. de 2026, 23:31 UTC

U.S. Core Producer Prices Expected to Rise 0.3% in August Amid Inflation Concerns and Potential Fed Rate Hikes

6 de set. de 2026, 23:21 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% Amid Caution Over Potential Fed Rate Hikes

6 de set. de 2026, 23:11 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid Investor Anticipation of Economic Catalysts

6 de set. de 2026, 22:41 UTC

Australia's Westpac Consumer Confidence report set for September 8, 2026, shows cautious optimism amid inflation concerns and rising investor confidence.

6 de set. de 2026, 22:31 UTC

Mexican Inflation Rate Expected to Continue Declining Trend Ahead of September 9 Release, Boosting Market Optimism.

6 de set. de 2026, 22:31 UTC

Mexico's Inflation Rate Release on September 9, 2026 Expected to Influence Market Dynamics Amid Global Economic Sentiment.

6 de set. de 2026, 22:31 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid mixed market expectations and rising optimism following increased buying activity.

6 de set. de 2026, 22:21 UTC

MBA 30-Year Mortgage Rate Release on September 9, 2026, Expected to Show Continued Upward Pressure Amid Inflation and Fed Policy Concerns.

6 de set. de 2026, 22:11 UTC

Brazil's Central Bank to Provide Key Insights on Monetary Policy Direction in Upcoming Interest Rate Readout Amid Market Uncertainty

6 de set. de 2026, 22:01 UTC

Japan's GDP Growth Forecasted at +1.1% for Q2 2026 Amid Cautious Optimism in Economic Recovery

6 de set. de 2026, 22:01 UTC

Japan's GDP Growth Rate Expected at +0.4% Amidst Rising Market Confidence and Global Economic Discussions

6 de set. de 2026, 21:51 UTC

Turkey's Central Bank Expected to Maintain 37% Interest Rate Amid Inflation Concerns Ahead of September Decision.

6 de set. de 2026, 21:51 UTC

UK Housing Market Faces Continued Pressure as RICS House Price Balance Forecast Improves Slightly to -0.28% Amid Weak Buyer Demand

6 de set. de 2026, 21:31 UTC

South Korea's August 2026 unemployment rate release on September 8 sparks cautious optimism amid recent job gains and inflationary pressures.

6 de set. de 2026, 21:11 UTC

UK Retail Sales Monitor YoY for August 2026 Expected to Show Modest 1.2% Increase Amid Cautious Consumer Sentiment and Economic Challenges

6 de set. de 2026, 21:01 UTC

Spain's Consumer Confidence report on September 8, 2026, shows rising optimism with an index increase to 81.2 amid recovering market sentiment and geopolitical concerns.

6 de set. de 2026, 21:01 UTC

Cautious Market Sentiment Ahead of South Africa's Q2 GDP Growth Rate Release Amid Global Economic Fluctuations

6 de set. de 2026, 21:01 UTC

South Africa's GDP Growth Rate Release on September 8, 2026 Sparks Market Optimism Amid Global Economic Factors.

6 de set. de 2026, 20:21 UTC

Japan's Current Account data set for release on September 7, 2026, forecasts a surplus of JPY 2.87 trillion amid cautious investor sentiment due to historical volatility in outcomes.

6 de set. de 2026, 19:01 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Expected to Reflect Volatile U.S. Inventory Trends Amid Geopolitical Tensions and OPEC+ Production Stability.

6 de set. de 2026, 18:51 UTC

Italy's Industrial Production Expected to Rise 0.3% in July Amidst Recent Declines and Economic Concerns

6 de set. de 2026, 18:31 UTC

France's Industrial Production Expected to Rise 0.3% in July Amid Economic Uncertainty

Comparação entre Pares

Variação de preço

Pliant Therapeutics Inc Previsão

Preço-alvo

By TipRanks

115.52% parte superior

Previsão para 12 meses

Média 2.5 USD  115.52%

Máximo 3 USD

Mínimo 2 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

0

Comprar

4

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat